Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2025 08:31 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
February 11, 2025 12:59 ET | Source: Sixty Degrees Pharmaceuticals

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.
January 08, 2025 08:02 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
May 15, 2024 13:45 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
January 22, 2024 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP
December 26, 2023 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the
August 30, 2023 07:32 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
August 15, 2023 07:31 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
July 12, 2023 12:29 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering

WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious...
April 26, 2023 07:34 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections

Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention,...